PATENT CLAIM ANALYSIS

Application Number: 16024021
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "186000"]

Abstract:
The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D  (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

Claim (Index 15):
A method for the treatment of a hepatitis C infection comprising administering a compound or salt of  claim 7  to a patient in need thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 94.0
- Lexical Diversity: 1.77941
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13482558', '14328312', '14972913', '15437117', '15271066']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7925659867243259
- 35 USC 102 Novelty (BERT): 0.5424385629194767
- Combined Prediction Score: 0.7675532443438409
- Mean Citation Score: 355.681352
- Max Citation Score: 397.37338
- Similarity Product: 300.5305394027185

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test